FindTrial
Sign In

Alisertib Enteric-Coated Tablets

DRUG2 trials

Sponsors

Puma Biotechnology Inc.

Conditions

Hormone receptor positive (HR+)Small Cell Lung Cancer (SCLC)human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)

Phase 2

A Phase 2 study of alisertib in combination with endocrine therapy in patients with HR+, HER2-negative recurrent or metastatic breast cancer
RecruitingCTIS2024-511497-79-00
Puma Biotechnology Inc.Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)
Start: 2024-12-30Target: 54Updated: 2025-12-23
A Phase 2 Study of Alisertib in Combination with Paclitaxel in Patients with Small Cell Lung Cancer
Not yet recruitingCTIS2026-525382-47-00
Puma Biotechnology Inc.Small Cell Lung Cancer (SCLC)
Target: 26Updated: 2026-07-28